Company Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases.
The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets.
Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn’s disease.
The company was founded in 2012 and is based in San Diego, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Barry Quart |
Contact Details
Address: 12265 El Camino Real, Suite 350 San Diego, California 92130 United States | |
| Phone | 858 727 1040 |
| Website | connectbiopharm.com |
Stock Details
| Ticker Symbol | CNTB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001835268 |
| CUSIP Number | 207523101 |
| ISIN Number | US2075231017 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Barry D. Quart Pharm.D. | Chief Executive Officer and Director |
| Dr. Zheng Wei Ph.D. | Co-Founder and Director |
| Dr. Wubin Pan M.B.A., Ph.D. | Co-Founder and Director |
| Jiang Bian J.D. | General Counsel and Chief Compliance Officer |
| Dr. Lei Sun Ph.D. | Vice President of Biologics and Head of CMC |
| Dr. Raul Collazo Ph.D. | Vice President and Global Head of Medical Affairs |
| Dr. Srikanth Pendyala M.D. | Senior Vice President of Clinical Development(Consultant) |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 6, 2024 | 6-K | Report of foreign issuer |
| Sep 5, 2024 | 6-K | Report of foreign issuer |
| Aug 2, 2024 | 6-K | Report of foreign issuer |
| Jul 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 12, 2024 | 6-K | Report of foreign issuer |
| Apr 16, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 16, 2024 | 6-K | Report of foreign issuer |
| Feb 27, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 27, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 13, 2024 | SC 13D | General statement of acquisition of beneficial ownership |